Creative Medical completes enrollment, treatment in FDA-cleared ADAPT trial of Olastrocel for chronic lower back pain

• Creative Medical Technology Holdings completed enrollment and treatment across its FDA-cleared ADAPT trial of CELZ-201 (Olastrocel) for chronic lower back pain.
• Results were already presented in prior interim readouts, showing encouraging early signs of pain and function improvement with a favorable safety profile.
• The FDA-cleared opioid-use expansion cohort also finished dosing, supporting evaluation in a more commercially relevant patient population.
• Spending tied to recruitment and treatment is expected to ease as the study shifts to follow-up, data maturation, RMAT evaluation, and Phase 3 planning.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Creative Medical Technology Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608200915PRIMZONEFULLFEED9813528) on August 20, 2026, and is solely responsible for the information contained therein.